This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clovis Oncology (CLVS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 1.56% and 3.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Clovis Oncology (CLVS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook
by Zacks Equity Research
Goldman Sachs lowers price target for Clovis' (CLVS) shares taking into account the risk of lower future revenues due to rising competition in the PARP inhibitor segment.
J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug
by Zacks Equity Research
J&J (JNJ) announces that the FDA has granted Breakthrough Therapy status to its PARP inhibitor, niraparib, for the treatment for advanced prostate cancer.
Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.
Clovis Gains Rights to Pre-Clinical Cancer Program for $12M
by Zacks Equity Research
Clovis (CLVS) enters into licensing and collaboration agreement with 3B Pharmaceuticals and acquires rights to FAP targeted radiopharmaceutical therapy for developing new cancer treatments.
Why Is Clovis (CLVS) Down 36.8% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
by Zacks Equity Research
Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
by Zacks Equity Research
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.
Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
by Zacks Equity Research
Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
by Zacks Equity Research
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
by Zacks Equity Research
Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.
Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 9.44% and 4.53%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?
by Zacks Equity Research
During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
Cronos (CRON) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when the company reports Q1 results.
Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis Focuses on Rubraca Label Expansion, Competition Stiff
by Zacks Equity Research
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
Company News For Apr 16, 2019
by Zacks Equity Research
Companies in the news are: ADSW, WM, APHA, CLVS and LYFT
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
by Zacks Equity Research
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.